Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02446093 · ClinicalTrials.gov registry record · Phase 2

Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic Adenocarcinoma

A Phase 2 study of Borderline Resectable Pancreatic Adenocarcinoma, sponsored by Candel Therapeutics.

Active
Registry status
Phase 2
Development phase
54
Enrollment target
3
Study locations

NCT02446093 is a Phase 2 study of Borderline Resectable Pancreatic Adenocarcinoma that is active but no longer recruiting, run by Candel Therapeutics. The registered enrollment target is 54 participants, above the 44-participant average among 7 other Borderline Resectable Pancreatic Adenocarcinoma trials with a reported enrollment target (23% higher). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02446093, a Phase 2 study of Borderline Resectable Pancreatic Adenocarcinoma, is active but no longer recruiting, sponsored by Candel Therapeutics.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
54 participants
Enrollment target
3
Study locations

Study Summary

The purpose of this study is to characterize the safety, preliminary efficacy, and immune biologic activity of CAN-2409 + prodrug (valacyclovir or acyclovir) in subjects with borderline resectable pancreatic cancer who are being treated with neoadjuvant chemoradiation (CR) or stereotactic body radiation therapy (SBRT). The Standard of Care (SOC) Control arm will be used as a benchmark for informal comparisons of efficacy, safety, and biomarkers.

Conditions Studied

Borderline Resectable Pancreatic Adenocarcinoma

Interventions

  • RADIATION Chemoradiation
  • PROCEDURE Surgery
  • RADIATION Stereotactic body radiation therapy
  • BIOLOGICAL Aglatimagene besadenovec

Study Locations (3)

Florida

  • Lee Health/Regional Cancer Center - Fort Myers

Ohio

  • Ohio State University - Columbus

Other

  • Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran - Mexico City

Trial Details

FieldValue
Enrollment Target 54 participants
Start Date 2015-10
Est. Completion 2026-07
Phase Phase 2

Sponsor

Candel Therapeutics

13 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02446093

The ClinicalTrials.gov registry entry for NCT02446093 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 44-participant average among 7 other Borderline Resectable Pancreatic Adenocarcinoma trials with a reported enrollment target (23% higher). The listed sponsor is Candel Therapeutics, which has 13 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Borderline Resectable Pancreatic Adenocarcinoma appearing as the primary indexed condition, and to 4 interventions - of which Chemoradiation is the first listed.

NCT02446093 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Florida, Ohio, Other.

Frequently Asked Questions

What is clinical trial NCT02446093 about?

NCT02446093 is a clinical study titled "Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic Adenocarcinoma". The purpose of this study is to characterize the safety, preliminary efficacy, and immune biologic activity of CAN-2409 + prodrug (valacyclovir or acyclovir) in subjects with borderline resectable pancreatic cancer who are being treated with neoadjuvant chemoradiation (CR) or stereotactic body radia...

What is the current status of trial NCT02446093?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 54 participants. The study started on 2015-10. Estimated completion is 2026-07.

What conditions does trial NCT02446093 study?

This clinical trial studies the following conditions: Borderline Resectable Pancreatic Adenocarcinoma.

What interventions are being tested in trial NCT02446093?

The interventions under investigation include: Chemoradiation (RADIATION), Surgery (PROCEDURE), Stereotactic body radiation therapy (RADIATION), Aglatimagene besadenovec (BIOLOGICAL).

Who is sponsoring clinical trial NCT02446093?

This trial is sponsored by Candel Therapeutics, which has 13 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02446093 being conducted?

This trial has 3 study locations across Florida, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Borderline Resectable Pancreatic Adenocarcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Borderline Resectable Pancreatic Adenocarcinoma

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.